Biotalys Nv · EURONEXT:BTLS
Biotalys Nv — Investor Presentation (2023)
28 slides from Biotalys Nv's investor presentation, 2023
Slide 1: Shaping a sustainable and safe food supply
Shaping a sustainable and safe food supply 1
Slide 2: Safe harbor statement
Safe harbor statement This presentation, including the oral presentation (together, the “Materials”) has been prepared by the management of Biotalys NV (the “Company”). The Materials must be treated confidentially and may not be distributed, passed on or otherwise disclosed. The Materials serve info
Slide 3: Biotalys’ ambition
Biotalys’ ambition Provide safe and sustainable alternatives to protect our food, ensure productivity and quality while preserving our environment, our soils and our health Challenges Requirements Biotalys’ solutions Differentiated and versatile 10b population by 20501 biocontrol platform Secure yie
Slide 4: Key facts
Key facts Approval of Founded in 2013 Belgium and US Close to 20 patent 75 FTEs1 first product IPO in 2021 locations families1 expected Q3 2023 Agricultural Technology company Developing novel protein-based The first product Evoca™,2 aims to focused on addressing food biocontrol solutions offer frui
Slide 5: Crop protection: a growing market
Crop protection: a growing market Total Crop Protection Market 20212 Regional Estimated evolution1 Estimated Crop Protection Region 2021 2022E Change 29% 25% market Asia Pacific 21.0 21.9 +4% 2022: $69.2b (+6.2%) 1 Latin America 16.4 19.2 +16.9% ~ $65B 2025E: $75b Europe, ME 16.3 15.7 -3.6% 13% and
Slide 6: Advantages of biological crop protection products drive a strong growing market
NOT FOR DISTRIBUTION Advantages of biological crop protection products drive a strong growing market Advantages of biologicals vs. chemicals Biological CP market expected to show double digit growth over Increase quality & safety Provide new tools Provide safe & the next years of produce by limiting
Slide 7: AGROBODY: Biocontrol by Biotalys
AGR@BODY” iocontrol by biotalys
Slide 8: AGROBODY Foundry – validated platform for antibody-based biocontrols
AGROBODY™ Foundry – validated platform for the generation of antibody-based biocontrols Similar affinity to conventional antibodies Single domain antibodies engineered from heavy-chain antibodies exploited for >25 years → High binding capacity to selected antigens VHH High stability Heavy-chain anti
Slide 9: AGROBODY Foundry – nature driven, designed for performance
AGROBODY FoundryTM – nature driven, designed for performance Current key crop pest and disease targets Targeted Discovery (High Throughput) Field Straightforward Delivery Development Regulatory Path Fungi Protein libraries VHH Insects Novel biocontrols Bacteria for a wide range of pests and diseases
Slide 10: AGROBODY Foundry combines the best of both worlds
AGROBODY Foundry™ combines the best of both worlds Sustainability Performance Discovery A numbers game Scalability Efficiency5 Consistency 108 Antibodies Thousands of hits ~€35m2 Multiple potential leads & diverse MoA ~8 years3 100,000 Synthesis €250m1 Chemicals 1 Lead + Backups (same MoA) 11 years1
Slide 11: Evoca is pending registration
EvocaTM is pending registration. This product is not currently registered for sale or use in the United States, the EU or elsewhere, and 11 is not being offered for sale.
Slide 12: Evoca™ – A novel tool for biocontrol
Evoca™ – A novel tool for biocontrol Performance on par with Contact activity for preventive synthetic chemical standards in IPM*- control of Botrytis cinerea (bunchrot) programs1 and powdery mildew Unique mode-of-action for resistance management: replacement of Up to 2/3 of residue reduction in IPM
Slide 13: Field trial results: Evoca™ outperforms leading chemical
NOT FOR DISTRIBUTION Field trial results: Evoca™ outperforms leading chemical Key Findings Evoca™ provides excellent preventative control of Botrytis bunch rot in grapevines Applying Evoca™ at flowering offers growers a clean start as the foundation of an IPM program Treat- ment Program Flowering Bu
Slide 14: Independent field trials by US public institutes
Independent field trials by US public institutes Continued demonstration of performance and consistency in independent IPM programs Untreated EVOCA™ Leading biocontrol IPM Grape – Botrytis bunch rot UC Davis Cooperative Extension Dr. Akif Eskalen Notes: IPM: Mevalone (3 plant terpenes) fb Pristine (
Slide 15: Regulatory timelines
NOT FOR DISTRIBUTION Regulatory timelines EPA regulatory path Data requirements endorsed by EFSA Biochemical Pesticide Applying for Low-Risk Classification Faster and cheaper registration process than chemicals No specific pathway for biologicals Submission Expected EPA State registrations Submissio
Slide 16: Product Pipeline
Product Pipeline
Slide 17: Innovative pipeline of protein-based biocontrols
Innovative pipeline of protein-based biocontrols Target Program Total Addressable Stage Target Crops Partnerships Market: $4.8bn2 Launch3 Botrytis, Powdery mildew Market calibration 2023 Botrytis, Powdery mildew $600m 2026 Botrytis, Powdery mildew, Anthracnose BioFun-61 $1.2bn 2028 Lepidoptera BioIn
Slide 18: Partnerships expanding validation and scope of technology
NOT FOR DISTRIBUTION Partnerships expanding validation and scope of technology • Research into leafspot disease for cowpeas • Long term strategic partnership leveraging Biotalys supporting smallholders’ livelihood AGROBODYTM Platform • Targeting discovery of a new, safe and efficient • Targeting bio
Slide 19: Continued exploration of potential applications throughout the food value chain
Continued exploration of potential applications throughout the food value chain Seed treatment Around harvest Retail Crop Protection Post-harvest Covered Other crops Segments ... Ag Industry Majors Food Protection Retail Distributors Shipper Packers Consumers Biocontrol Specialists Integrated Food I
Slide 20: Manufacturing and platform optimizations delivering a profitable pipeline
NOT FOR DISTRIBUTION Manufacturing and platform optimizations delivering a profitable pipeline Production efficiency 1 Protein expression + process optimization Production costs Economies of scale 2 Campaign run in larger bioreactors Towards Evoca commercial Rate reduction 1 3 Intrinsic activity + f
Slide 21: De-risk, accelerate and grow through strategic partnerships
De-risk, accelerate and grow through strategic partnerships Science and Technology Product Development Distribution Exclusive US Pipeline Product Manufacturing Regulatory 21 21
Slide 22: Financials
Financials reinventing food protection
Slide 23: Key financials – FY 2022
Key financials – FY 2022 In € thousand December 31, 2022 December 31, 2021 Other operating income 2,949 1,995 Research and development expenses (18,813) (13,880) General and administration expenses (5,081) (4,905) Marketing expenses (1,586) (1,289) Operating loss (22,531) (18,079) Loss for the perio
Slide 24: Listed on Euronext Brussels
Listed on Euronext Brussels Code: Analyst coverage: BTLS Gimv 13.9 % Guy Sips KBC Securities Sofinnova 13.7 % AvH 13.0 % Christian Faitz PMV 8.1 % Kepler Cheuvreux AIF 7.0 % Sebastian Bray Shareholder Biovest 6.6 % Berenberg structure Madeli 6.3 % K&E 6.0 % Other 25.4 % Percentages rounded – non dil
Slide 25: Value creation designed through pipeline advancement, partnerships & commercial growth
Value creation designed through pipeline advancement, strategic key partnerships & commercial growth Sales In-licensing growth to accelerate and market AGROBODY growth expansion Pipeline Foundry™ progression expansion Strategic R&D and Evoca™ partnerships expansion registration Strategic production
Slide 26: Outlook 2023 – continuous value creation with major milestones
Outlook 2023 – continuous value creation with major milestones • Obtain product approval in the US, paving the way to advance the rest of Biotalys’ pipeline through the regulatory process • Initiate multi-year market calibration in the US with partner Biobest for highest fruit & vegetable market seg
Slide 27: Team of professionals with extensive industry experience
Team of professionals with extensive industry experience Patrice Sellès Luc Maertens Wim Ottevaere Carlo Boutton Patrick McDonnell CEO COO CFO (until end of June 2023) CSO CBO Simon E. Moroney Michiel van Lookeren Piet Bevernage Johan Cardoen Chairman Campagne Non-Executive Director Independent Dire
Slide 28: IR@biotalys.com www.biotalys.com
IR@biotalys.com www.biotalys.com